Video

Dr. Abida on Genetic Testing for Prostate Cancer

Author(s):

Wassim Abida, MD, PhD

In Partnership With:

Wassim Abida, MD, PhD, medical oncologist, Developmental Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses genetic testing for patients with prostate cancer.

Wassim Abida, MD, PhD, medical oncologist, Developmental Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses genetic testing for patients with prostate cancer.

The process of genetic testing for patients is not complicated, but the difficulty is figuring out who should be tested and what specific genes should be investigated, explains Abida.

Genetic testing is very important because it can affect decisions regarding treatment and screening for patients with prostate cancer and their families, states Abida.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Related Content
James J. Harding, MD, of Memorial Sloan Kettering Cancer Center
November 21st 2024

Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC

Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center
August 22nd 2024

Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer

Sandy Srinivas, MD, of Stanford Medicine
November 21st 2024

Kidney Cancer NCCN Guidelines Receive Major Updates, Prostate Cancer Adds Targeted Agents

Nam Bui, MD, sarcoma specialist, clinical assistant professor, medicine, Stanford Cancer Institute; Ciara Kelly, MBBCh, BAO, interim clinical director, Sarcoma Oncology Service, Memorial Sloan Kettering Cancer Center
July 18th 2024

Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa

177Lu-PSMA-I&T in PSMA+ mCRPC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 13th 2024

177Lu-PSMA-I&T Meets rPFS End Point in PSMA+ mCRPC

Here is your snapshot of all therapeutic options that the FDA approved in October 2024.
November 5th 2024

OncLive’s October Roundup of Key FDA Approvals in Oncology